IDEAYA Biosciences, Inc.
IDYA
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.8B
$39.86
▼ -0.28%
P/E
-20.55
Mkt Cap
$3.8B
52-Wk Range
$23.23–$42.68
52-Week Range
$23.23 - $42.68
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 70.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Synthetic lethality platform targeting genetic vulnerabilities in cancer cells
- Strategic partnerships with Pfizer, GlaxoSmithKline, and leading research institutions
- Biomarker-driven patient selection enabling higher clinical trial success rates
- Differentiated pipeline addressing underserved patient populations with defined mutations
Bear Case
1 risk
- Low volatility (beta -0.1).
Growth
Revenue decline expected
Clinical advancement of IDE397 and IDE196 through Phase I/II trials
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+26.6% over 3m
Quality
Loss-making
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying IDYA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
Most recent quarter reported revenue of $8.9M. Reported EPS of -$1.22.
Reported EPS · last 4Q
Q2 26
-$1.22
Q1 26
-$1.11
Q4 25
-$0.94
Q3 25
$1.35
Revenue trend · last 8Q
—
+78%
—
—
—
+55%
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$7.0M
$0
$0
$207.8M
$10.9M
$6.6M
$8.9M
Margins · last 8Q
Gross
—
Operating
—
Profit
-1269.6%
Wall Street consensus
8 analysts · 88% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
88%
Hold
13%
Sell
0%
Median Price Target
—
Latest: Citi · Sep 1, 2026
vs Industry
How IDYA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related